BAT2 and BAT3 polymorphisms as novel genetic risk factors for rejection after HLA-related SCT.

The genetic background of donor and recipient is an important factor determining the outcome of allogeneic hematopoietic SCT (allo-HSCT). We applied whole-genome analysis to investigate genetic variants-other than HLA class I and II-associated with negative outcome after HLA-identical sibling allo-HSCT in a cohort of 110 β-Thalassemic patients. We identified two single-nucleotide polymorphisms (SNPs) in BAT2 (A/G) and BAT3 (T/C) genes, SNP rs11538264 and SNP rs10484558, both located in the HLA class III region, in strong linkage disequilibrium between each other (R(2)=0.

Detection of the new HLA-DRB1*14:129 allele in a voluntary stem cell donor.

The new allele, officially named HLA DRB1*14:129, differs from HLA DRB1*14:54 in exon 2.

Characterization of the novel HLA-C*16:07:02 allele in a family of Benin origin.

The novel allele HLA-C*16:07:02 differs from HLA-C* 16:07:01 by a silent nucleotide substitution at codon 220 (TAC → TAT).

The novel HLA-C*06:58 allele, identified by sequence-based typing in an Italian family.

The novel HLA-C allele C*06:58 shows one nucleotide change from C*06:02:01:01 at nt 366 from G to A, resulting in an amino acid change at codon 98 of exon 3 from Met to Ile.

Identification of a novel HLA-B*07 allele in an Iranian family: B*0769.

New allele B*0769 showed one nucleotide difference with B*0732 at codon 272 (TTC-->TGC).